Driven by a powerful mission and vision to
bring real change in people's lives.
Empowering Health
Through Innovation
Driven by a powerful mission and vision to
bring real change in people's lives.
Empowering Health
Through Innovation
Driven by a powerful mission and vision to
bring real change in people's lives.
Who we are
One of the Leading Global Pharmaceutical Companies, EU GMP–certified Egyptian manufacturer providing innovative diversified specialty care treatments in diffirent therapeutic areas, with a strong presence covering Africa and GCC, to deliver cost-effective critical solutions to healthcare practitioners and their patients across the continent.
News & Updates
Marcyrl Group celebrates the launch of Ruxotop
Collaborating with The Egyptian Drug Authority (EDA) Marcyrl Group launched a new innovative product with several KOLs in dermatology from around Egypt.
The 64th Annual International Congress of The Egyptian Society of Chest Diseases & Tuberculosis 2023
Marcyrl Group contributes significantly to The Egyptian Society of Chest Diseases and Tuberculosis through pharmaceutical products at the 64th Annual International Congress of The Egyptian Society of Chest Diseases & Tuberculosis 2023.
Marcyrl Group always provides different training for the employees to improve their talent and skills by sharing experiences, continuing learning, and building relationships.
Facilities with EU GMP-certified lines and cold chain capabilities 2000+ Members in the team
1
Leader in hormonal and respiratory products in Egypt
Transforming Lives through
Innovation and Excellence
Get to know our products
We strive to enhance the lives of patients by providing them with accessible and affordable healthcare solutions.
Let’s work together
Export Capabilites
Marcyrl Pharmaceutical Industries, an Egyptian pharmaceutical manufacturer, has secured investment from Development Partners International (DPI) and Amethis. They focus on specialty generics, to improve access to critical care drugs across Africa. Marcyrl’s growth includes expanding its product portfolio and addressing the demand for affordable specialty generics in Africa. The investment underscores the significance of the pharmaceutical sector and Marcyrl’s commitment to bridging healthcare gaps in the continent.
Capitalizing on our EU-approved GMP sites, Marcyrl Pharmaceutical Industries is exporting a wide range portfolio of medicines to 23 export markets including GCC, LEVANT, and AFRICA
Our ambitious plan to expand our export business in Africa, CIS, GCC, and LATAM.
Jobs that make the world a better place
We strive to enhance the lives of patients by providing them with accessible and affordable healthcare solutions.
Why partner with Marcyrl
A Wide portfolio including a niche in hormonal and respiratory
325 SKUs mainly in chronic disease areas; 300 SKUs in the pipeline
A portfolio spanning 15 TAs, in particular female health/fertility, cardiovascular, urology, neuroscience, gastroenterology, etc.
Niche in novel, high-complexity products (in particular hormonal, respiratory)
Why partner with Marcyrl
Wide portfolio including niche in hormonal and respiratory products
Top-notch R&D and manufacturing capabilities with EU GMP-certified facilities
Cost competitiveness built on
world-class procurement and lean operations – Track record of
effective cost containment despite sharp currency devaluation
2017-2021; Leadership in the tender market (11% of sales in 2021)
Why partner with Marcyrl
Track record of registering and commercializing in export markets
Existing export footprint
in 23 countries outside of Egypt
107 successful registrations in export markets,
106 products under registration
Why partner with Marcyrl
Strong management team, backed by leading institutional investors
Experienced management with diverse expertise
Entry of DPI and Amethis in 2023
- combined AUM of USD 3.6 billion,
Africa focused with strong pharma exposure
